MCK McKesson
A dominant drug-distribution toll road, priced near fair value; thin margins leave little room for error.
The story
McKesson is the largest US drug distributor, one of three firms (with Cencora and Cardinal) that together move over 90% of US pharmaceutical volume. Scale, logistics density and entrenched manufacturer and pharmacy contracts give it a durable but thin-margin franchise. Growth comes from GLP-1 volume, specialty and oncology distribution, and the high-margin RxTS and biopharma services businesses. It is a mature, capital-light compounder: negative working capital funds growth, and buybacks shrink the share count.
Growth starts near 10% on GLP-1 and specialty volume. It fades toward nominal healthcare spending growth because GLP-1 pass-through revenue carries almost no margin. Margin rises modestly from 1.6% to 1.8% as oncology, specialty and RxTS grow in the mix, partly offset by the planned Medical-Surgical separation. Sales-to-capital is set at 40, below the trailing 94, to reflect acquisitions in oncology and tech. Beta of 0.85 matches defensive, non-cyclical demand. The 10-year horizon fits a durable oligopoly with a long specialty runway but no pricing power.
Value drivers
| Revenue growth (Y1) | 10.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 1.8% |
| Years to target margin | 5 |
| Sales-to-capital | 6.00 |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.5% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 15.35B |
| PV of terminal value | 71.95B |
| Equity value | 82.57B |
| ÷ shares → per share | $708.23 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 452.08B | 10.0% | 1.7% | 6.21B | 6.85B | -639.37M | -589.03M |
| 2 | 494.02B | 9.3% | 1.7% | 6.92B | 6.99B | -72.59M | -61.60M |
| 3 | 536.29B | 8.6% | 1.7% | 7.65B | 7.04B | 608.02M | 475.41M |
| 4 | 578.30B | 7.8% | 1.8% | 8.41B | 7.00B | 1.40B | 1.01B |
| 5 | 619.42B | 7.1% | 1.8% | 9.17B | 6.85B | 2.31B | 1.54B |
| 6 | 659.00B | 6.4% | 1.8% | 9.75B | 6.60B | 3.16B | 1.93B |
| 7 | 696.34B | 5.7% | 1.8% | 10.31B | 6.22B | 4.08B | 2.30B |
| 8 | 730.77B | 4.9% | 1.8% | 10.82B | 5.74B | 5.08B | 2.63B |
| 9 | 761.63B | 4.2% | 1.8% | 11.27B | 5.14B | 6.13B | 2.93B |
| 10 | 788.28B | 3.5% | 1.8% | 11.67B | 4.44B | 7.22B | 3.18B |
Key risks
- GLP-1 pricing cuts or a shift to direct-to-consumer channels that remove distributor volume
- Drug pricing reform (IRA negotiation, PBM/340B changes) compressing distribution economics
- Loss or repricing of a major customer contract, or residual opioid litigation
Catalysts
- Medical-Surgical spin-off simplifying the story and unlocking value
- Continued oncology/specialty platform expansion and RxTS growth driving margin mix